

MARKET REPORT



Kinase Inhibitors Market: By Product (Angiogenesis, m-TOR, BRAF and MEK, Bcr-Abl Tyrosine-Kinase (TKI), EGFR, PI3K, Aurora-Kinase Inhibitors, & Others), By End-User (Hospitals, Research Labs, & Others) & By Region-Forecast (2016-2021)

BioPortfolio

Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Kinase Inhibitors Market: By Product (Angiogenesis, m-TOR, BRAF and MEK, Bcr-Abl Tyrosine-Kinase (TKI), EGFR, PI3K, Aurora-Kinase Inhibitors, & Others), By End-User (Hospitals, Research Labs, & Others) & By Region-Forecast (2016-2021)

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Kinase Inhibitors Market: By Product (Angiogenesis, m-TOR, BRAF and MEK, Bcr-Abl Tyrosine-Kinase (TKI), EGFR, PI3K, Aurora-Kinase Inhibitors, & Others), By End-User (Hospitals, Research Labs, & Others) & By Region-Forecast (2016-2021)

Kinase inhibitors are enzymes which selectively block the action of other enzymes, and help in regulation of the activity of other proteins and, the activities of cells. Globally, growing focus of pharmaceutical companies on R&D to come up with potential medicines for treatment of cancers, rise in the in aging population, and increasing incidence and frequency of various cancers are the prime growth drivers of global kinase inhibitors market. In addition, increase in adoption of kinase inhibitors for newer applications, and emerging economies such as China, India and others, will create new opportunities for global kinase inhibitors market. However, The research and development having higher cost, complex approvals processes, and stringent government policies are the key restraints for global kinase inhibitors market.

This report identifies the global kinase inhibitors market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global kinase inhibitors market.

Geographically North America dominated global kinase inhibitors market, and Asia Pacific is projected to have fastest growth, owing to rapidly increasing aging population, growing incidence and prevalence of cancer patients and modernizing healthcare infrastructure in the developing nations such as China, and India in this region. Among all the end-users, hospital segment has the highest market share in global kinase inhibitors market.

This report segments global kinase inhibitors market on the basis of product, end-user, and regional market as follows:

Kinase Inhibitors Market, By Product: Angiogenesis Inhibitors, m-TOR Inhibitors, BRAF and MEK Inhibitors, Bcr-Abl Tyrosine-Kinase Inhibitors (TKI), EGFR Inhibitors, PI3K Inhibitors, Aurora-Kinase Inhibitors, and Others

The report has focused study on kinase inhibitors market by basis of end-user such as: Hospitals, Research Labs, and Others

This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the kinase inhibitors market. Some of the major companies' profiles in detail are as follows:

Takeda Pharmaceutical Company Limited

Boehringer Ingelheim GmbH

AstraZeneca, Eisai Co., Ltd.

Bristol-Myers Squibb

Glaxo SmithKline

Additional Details

Publisher : Industry ARC

Reference : HCR 0236

Number of Pages : 0

Report Format : PDF

Publisher Information :



IndustryARC is the Leading Provider of Market Research Reports, Custom Consulting Services, Data Analytics and Industry Analysis. Our goal is to provide the right information required by the stakeholder at the right point of time, in a format which assists an intelligent and informed decision making process!

We provide profound information with a proactive collaboration with the clients to identify new opportunities and guide them to find the best strategy for finding growth avenues. Our in-depth Research Reports with analysis done by experienced consultants and inputs from industry experts, Key Opinion Leaders (KOLs) span multiple sectors such as:

Table Of Contents for Kinase Inhibitors Market: By Product (Angiogenesis, m-TOR, BRAF and MEK, Bcr-Abl Tyrosine-Kinase (TKI), EGFR, PI3K, Aurora-Kinase Inhibitors, & Others), By End-User (Hospitals, Research Labs, & Others) & By Region-Forecast (2016-2021) [Report Updated: 03-03-2016]

- 1. Kinase Inhibitors Market – Market Overview2. Executive Summary 3. Market Landscape3.1. Market Share Analysis3.2. Comparative Analysis3.3. Product Benchmarking3.4. End User Profiling3.5. Top 5 Financials Analysis4. Kinase Inhibitors Market– Market Forces4.1. Drivers4.1.1. Growing focus of pharmaceutical companies on R&D to come up with potential medicines for treatment of cancers4.1.2. Rise in the in aging population4.1.3. Increasing incidence and frequency of various cancers4.2. Restraints4.2.1. The research and development having higher cost4.2.2. Complex approvals processes4.2.3. Stringent government policies4.3. Opportunities4.3.1. Emerging economies4.3.2. Increase in adoption of kinase inhibitors for newer applications4.4. Challenges4.5. Porter’s Five Forces Analysis4.5.1. Bargaining Power of Suppliers4.5.2. Bargaining Power of Buyers4.5.3. Threat of New Entrants4.5.4. Threat of Substitutes4.5.5. Degree of Competition5. Kinase Inhibitors Market, By Product 5.1. Angiogenesis Inhibitors5.2. m-TOR Inhibitors5.3. BRAF and MEK Inhibitors5.4. Bcr-Abl Tyrosine-Kinase Inhibitors (TKI)5.5. EGFR Inhibitors5.6. PI3K Inhibitors5.7. Aurora-Kinase Inhibitors5.8. Others6. Kinase Inhibitors Market, By End-User 6.1. Hospitals6.2. Research Labs 6.3. Others7. Kinase Inhibitors Market, By Geography7.1. Europe7.1.1. Germany7.1.2. France7.1.3. Italy7.1.4. Spain7.1.5. Russia7.1.6. U.K.7.1.7. Rest of Europe7.2. Asia Pacific7.2.1. China7.2.2. India7.2.3. Japan7.2.4. South Korea7.2.5. Rest of Asia-Pacific7.3. North America 7.3.1. U.S.7.3.2. Canada7.3.3. Mexico7.4. Rest of the World (RoW)7.4.1. Brazil7.4.2. Rest of RoW8. Kinase Inhibitors – Market Entropy8.1. Expansion8.2. Technological Developments8.3. Merger & Acquisitions, and Joint Ventures8.4. Supply- Contract9. Company Profiles 9.1. Takeda Pharmaceutical Company Limited9.2. Boehringer Ingelheim GmbH9.3. AstraZeneca, Eisai Co., Ltd.9.4. Bristol-Myers Squibb9.5. Glaxo SmithKline9.6. Incyte Corporation9.7. Bayer AG9.8. Pfizer Inc.9.9. Eisai Co., Ltd.9.10. Novartis AG*More than 40 Companies are profiled in this Research Report, Complete List available on Request**Financials would be provided on a best efforts basis for private companies"10. Appendix10.1. Abbreviations10.2. Sources10.3. Research Methodology10.4. Expert Insights

List Of Tables in Kinase Inhibitors Market: By Product (Angiogenesis, m-TOR, BRAF and MEK, Bcr-Abl Tyrosine-Kinase (TKI), EGFR, PI3K, Aurora-Kinase Inhibitors, & Others), By End-User (Hospitals, Research Labs, & Others) & By Region-Forecast (2016-2021) [Report Updated: 03-03-2016]

No

How to Buy...

Kinase Inhibitors Market: By Product (Angiogenesis, m-TOR, BRAF and MEK, Bcr-Abl Tyrosine-Kinase (TKI), EGFR, PI3K, Aurora-Kinase Inhibitors, & Others), By End-User (Hospitals, Research Labs, & Others) & By Region-Forecast (2016-2021) [Report Updated: 03-03-2016]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/80267>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$5250** | Single User Price
- \$6250** | Site License Price
- \$8450** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.